Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Doses of ALY688-SR in Generally Healthy Overweight or Obese Adults
First in human study of ALY688-SR administered as a subcutaneous injection
A Phase 1, Bioequivalence Trial Evaluating the Pharmacokinetic and Pharmacodynamic Biosimilarity of SBS6002 Versus Neulasta® Following Subcutaneous Administration to Healthy Volunteers
A Multicenter, Randomized, Double Blind, Placebo-Controlled, Phase 3 Studyto Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illnessin the Elderly
100 Clinical Results associated with INC Research Australia Pty Ltd
0 Patents (Medical) associated with INC Research Australia Pty Ltd
100 Deals associated with INC Research Australia Pty Ltd
100 Translational Medicine associated with INC Research Australia Pty Ltd